Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00001360
Other study ID # 930170
Secondary ID 93-M-0170
Status Recruiting
Phase
First received
Last updated
Start date September 17, 1993

Study information

Verified date November 13, 2023
Source National Institutes of Health Clinical Center (CC)
Contact NIMH LBC Volunteer
Phone (301) 827-5157
Email nimhlbcvolunteer@mail.nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to use brain imaging technology to measure changes in blood flow to areas in the brain as individuals perform intellectual tasks. This study will use functional magnetic resonance imaging (fMRI) to examine blood flow to areas of the brain as participants engage in tasks associated with visual perception, visual recognition, and memory.


Description:

Objective: Our goal is to study the functional organization of the intact human brain by combining cognitive tasks and neuroimaging. Functional magnetic resonance imaging (fMRI), magnetoencephalography (MEG) and electroencephalography (EEG) will be used to measure brain activity in healthy human subjects engaged in performing cognitive tasks. These tasks will address specific questions concerning the neural systems that mediate perception, attention, memory, decision-making, emotion, plasticity and social interactions. fMRI and MEG, respectively, will be employed to investigate the spatial and temporal aspects of these neural systems. Study Population: Normal volunteer participants aged 18-65, who are in good general health will be recruited from the local community and studied under this minimal risk protocol. Design: Subjects will perform cognitive tasks in behavioral and/or neuroimaging sessions (fMRI or MEG). Outcome Measures: Behavior as performance on cognitive tasks, and brain activity (fMRI and MEG) will be combined to yield information about the neural correlates and processes underlying different aspects of human cognition including visual perception, memory, learning, emotion, social cognition, decision-making and attention.


Recruitment information / eligibility

Status Recruiting
Enrollment 4100
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility - INCLUSION CRITERIA: Healthy adults, with at least a high school education, aged 18 to 65 years, will be recruited to participate in the study. EXCLUSION CRITERIA: Subjects will be excluded if they: - are an NIMH employee or a relative - have evidence of, or a history of: - major medical, neurological or psychiatric illness - serious head injury - learning disability-drug or alcohol abuse or dependence in the past 3 months, except nicotine -are taking prescription drugs or supplements that may affect brain function- -have serious vision or hearing problems In addition to the above, additional exclusion criteria apply for all MRI studies: - Female subjects who are pregnant or have a positive pregnancy test 24 hours prior to an experiment will be excluded from neuroimaging studies. - All subjects will be questioned prior to MRI scanning for possible occupational exposure to metal slivers or shavings, which may have become accidentally lodged in the tissues of the head or neck. Subjects with surgical clips or shrapnel in or near the brain or blood vessels, subjects with cochlear implants, subjects with any metallic body in the eye or CNS, and subjects with any form of implant wire or metal device which may concentrate radiofrequency fields will be excluded from MRI scanning experiments because of possible risks during MRI scanning. Those whose history is suggestive of such a problem will also be excluded from the MRI portion of the experiments. They may still participate in the behavioral and MEG experiments. - Subjects unable to lie flat on their back for up to 2 hours may not be eligible to participate in MRI scans.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
0-15 Water


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Andersen RA, Asanuma C, Essick G, Siegel RM. Corticocortical connections of anatomically and physiologically defined subdivisions within the inferior parietal lobule. J Comp Neurol. 1990 Jun 1;296(1):65-113. doi: 10.1002/cne.902960106. — View Citation

Baizer JS, Ungerleider LG, Desimone R. Organization of visual inputs to the inferior temporal and posterior parietal cortex in macaques. J Neurosci. 1991 Jan;11(1):168-90. doi: 10.1523/JNEUROSCI.11-01-00168.1991. — View Citation

Barbas H, Mesulam MM. Organization of afferent input to subdivisions of area 8 in the rhesus monkey. J Comp Neurol. 1981 Aug 10;200(3):407-31. doi: 10.1002/cne.902000309. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cognitive tasks and neuroimaging. Cognitive tasks and neuroimaging. ongoing
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01579149 - A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent Phase 1
Completed NCT01591850 - A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers Phase 1
Completed NCT01461967 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers Phase 1